CARLSBAD, Calif., April 9, 2020 /PRNewswire/ -- On February 26, 2020, Active Motif announced the successful isolation of antibodies from patients in China recovering from 2019 Coronavirus related pneumonia (COVID-19). The full suite of antibodies is now available for research as well as commercial applications.
"The discovery and expression of a full human antibody against the COVID-19 virus is of great significance for the research community as well as for the development of diagnostic tests and treatments," noted Ted DeFrank, CEO of Active Motif. "Our ability to scale up production and provide the global research community with access to our portfolio of antibodies is our company's first contribution to the fight against this pandemic." Active Motif, in collaboration with Fudan University and its affiliated Public Health Clinical Center, used its proprietary single-cell AbEpic™ screening technology to isolate antibodies from patients in China recovering from 2019 Coronavirus related pneumonia (COVID-19). The patient samples were screened to obtain whole human IgG antibody clones that have been sequenced, expressed and characterized for binding directly to the COVID-19 Coronavirus, S1 Protein. Joe Fernandez, Chairman and Founder of Active Motif stated, "We believe we are one of the first laboratories in the world to achieve isolation and expression of a full human antibody isolated directly from patients infected with Coronavirus."
For more information, please contact Ted DeFrank ([email protected]).
About Active Motif
Active Motif, Inc. is dedicated to developing, manufacturing and delivering epigenetics-based research tools to analyse nuclear function. Its customers include life scientists from academic and government institutions, biotechnology and pharmaceutical companies, hospitals and reference laboratories. Active Motif operates globally through its corporate headquarters in Carlsbad, California and offices in Shanghai China, Tokyo Japan and La Hulpe Belgium. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers.
View original content:http://www.prnewswire.com/news-releases/active-motif-launches-a-portfolio-of-recombinant-covid-19-antibodies-the-first-full-human-antibodies-derived-from-patients-infected-with-the-2019-coronavirus-now-available-for-research-and-commercial-use-301038697.html
SOURCE Active Motif